Tech Company Financing Transactions
Theregen Funding Round
Sanderling Ventures participated in a $1.5 million Series A capital raise for Theregen. The financing was announced on 1/17/2006.
Transaction Overview
Company Name
Announced On
1/17/2006
Transaction Type
Venture Equity
Amount
$1,500,000
Round
Series A
Investors
Sanderling Ventures (Timothy Mills)
Proceeds Purpose
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
225 Bush St. 16th Floor
San Francisco, CA 94105
USA
San Francisco, CA 94105
USA
Phone
Website
Email Address
Overview
Theregen, Inc. is a regenerative medicine company that is developing cell-based therapies for cardiovascular indications. Anginera, Theregen's lead product, is an epicardial patch designed to address ischemia and induce arteriogenesis in patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rob Abrams
Chief Medical Officer
Gary Gentzkow
VP - Bus. Development
Gilbert Mintz
VP - Operations
Gianine Figliozzi
Browse more venture capital transactions:
Prev: 1/17/2006: OmniGuide Surgical venture capital transaction
Next: 1/17/2006: TeleCIS Wireless venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs